Neogenomics (NEO) Payables (2010 - 2026)

Neogenomics has reported Payables for 17 years, with the latest figure at $25.9 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 88.08% year-over-year to $25.9 million; the trailing twelve-month figure through Mar 2026 stood at $25.9 million (down 88.08% YoY), and the FY2025 full-year result was $23.1 million, down 89.62% from the prior year.
• Payables for Q1 2026 stood at $25.9 million, up from $23.1 million in the prior quarter.
• The five-year high for Payables was $222.4 million in Q4 2024, with the low at $13.7 million in Q3 2022.
• Historically, Payables has averaged $67.1 million across 5 years, with a median of $22.6 million in 2025.
• Annual changes were most pronounced in 2024 — Payables surged 1189.84% — and 2025, when it plunged 89.62%.
• Neogenomics' Payables stood at $20.5 million in 2022, then decreased by 0.86% to $20.3 million in 2023, then jumped by 993.66% to $222.4 million in 2024, then sank by 89.62% to $23.1 million in 2025, then grew by 12.16% to $25.9 million in 2026.
• The last three Payables figures came in at $25.9 million (Q1 2026), $23.1 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.